| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 544349000 | Bicyclo ring system having the diazine ring as one of the cyclos | 73 |
| 20090131668 | 4-oxo-4,6,7,8-Tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds - Compound of formula (I): | 05-21-2009 |
| 20100152446 | Piperidine Derivatives - The present invention relates to piperidine derivatives of formula (I) | 06-17-2010 |
| 20130023660 | Carboxamide Compounds and Methods for Using the Same - Disclosed are carboxamide compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure | 01-24-2013 |
| 20130296564 | SYNTHESIS OF [2.2.2]-DIAZABICYCLIC RING SYSTEMS - Herein we describe compositions and methods for the synthesis of [2.2.2]-diazabicyclic structures comprising a domino reaction sequence involving aldol condensation, alkene isomerization, and intramolecular hetero-Diels-Alder cycloaddition. Excellent diastereofacial control during the cycloaddition is enforced with a removable chiral phenyl aminal diketopiperazine substituent. The reaction sequence rapidly generates molecular complexity and is competent with both enolizable and non-enolizable aldehyde substrates. This method provides an efficient route to [2.2.2]-diazabicyclic structures, common to bioactive prenylated indole alkaloids such as the brevianamides and stephacidins. | 11-07-2013 |
| 20140148599 | PREVENTIVE OR THERAPEUTIC AGENT FOR PAIN ASSOCIATED WITH HERPES ZOSTER IN ACUTE PHASE | 05-29-2014 |
| 544350000 | Three or more ring hetero atoms in the bicyclo ring system | 44 |
| 20090018336 | Racemization process of R-zopiclone - In one of the embodiments, the present invention provides a racemization process comprising: removing the organic solvent from a mother liquor comprising R-zopiclone malate, eszopiclone malate and an organic solvent to obtain a mixture of R-zopiclone malate and eszopiclone malate; mixing the mixture with water to obtain a solution; neutralizing R-zopiclone malate and eszopiclone malate in the solution to obtain a precipitate of R-zopiclone and eszopiclone; filtering the precipitate; mixing the precipitate of R-zopiclone and eszopiclone with DBU and an organic inert solvent having a boiling point of at least 80° C.; heating; and cooling to obtain a zopiclone racemate. | 01-15-2009 |
| 20090036681 | PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS - The present invention refers to a process for the resolution into one of its enantiomers of the racemate of compound of formula (I): | 02-05-2009 |
| 20090076272 | Polymorphs of eszopiclone malate - The present invention provides crystalline Eszopiclone malate form II, crystalline Eszopiclone form V, processes from preparing the crystalline Eszopiclone malate form II or V, pharmaceutical compositions comprising the crystalline Eszopiclone malate form II or V and methods of treating insomnia comprising administering the crystalline Eszopiclone malate form II or V. | 03-19-2009 |
| 20090099359 | ESZOPICLONE PROCESS - Eszopiclone is prepared by reacting zopiclone with an enatiomerically pure di-p-toluoyl tartaric acid, recovering a solid salt, and reacting a solid salt with a base. Zopiclone is prepared by reacting 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]-pyrazine with 1-chlorocarbonyl-4-methylpiperazine hydrochloride. | 04-16-2009 |
| 20090198058 | Process for Preparation of Dextrorotatory Isomer of 6-(5- chloro-pyrid-2-yl)-5-[(4-methyl -1-piperazinyl) carbonyloxy] -7-oxo-6,7-dihydro-5H-pyrrolo [3,4-b] pyrazine (Eszopiclone) - Disclosed herein is the process for preparation of 6-(5-chloro-pyrid-2-yl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine (Zopiclone), its resolution to get the dextrorotatory isomer of formula (I) substantially free of R(−) enantiomer and recovery of key raw material i.e. 6-(5-chloro pyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]pyrazine from the R-isomer of Zopiclone followed by conversion of the recovered compound to get pure Eszopiclone (I) in high yield and high purity. | 08-06-2009 |
| 20100022771 | REACTION APPARATUS, AND REACTION METHOD - The present invention is directed at obtaining a high yield of a target substance and simultaneously securing high productivity. | 01-28-2010 |
| 20100029943 | METHODS FOR PREPARING ESZOPICLONE CRYSTALLINE FORM A, SUBSTANTIALLY PURE ESZOPICLONE AND OPTICALLY ENRICHED ESZOPICLONE - The present invention provides methods for preparing eszopiclone Form A, substantially chemically pure eszopiclone, or eszopiclone with low level(s) of residual solvent(s). The present invention also provides eszopiclone with low level(s) of residual solvent(s). The present invention also provides a process for optical enrichment of eszopiclone free base. For instance, one of the embodiments of the invention is directed to a method of preparing eszopiclone Form A, wherein the method comprises crystallizing eszopiclone free base from a solvent selected from the group consisting of isopropanol (IPA), methyl isobutyl ketone (MIBK), acetone, n-butanol, i-butanolisobutanol, 2-butanol, tetrahydrofuran (THF), dimethyl carbonate, methanol, ethanol, ethyl lactate, dimethylformamide (DMF), carbon tetrachloride, toluene, iso-butyl acetate and mixtures thereof. | 02-04-2010 |
| 20100041885 | CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE - A Sitagliptin phosphate characterized by data selected from the group consisting of: a powder XRD pattern with peaks at 4.7, 13.5, 17.7, 18.3, and 23.7±0.2 degrees two theta; a powder XRD pattern with peaks at about 4.7, 13.5, and 15.5±0.2 degrees two theta and at least another two peaks selected from the following list: 14.0, 14.4, 18.3, 19.2, 19.5 and 23.7±0.2 degrees two theta; and a powder XRD pattern with peaks at about 13.5, 19.2, and 19.5±0.2 degrees two theta and at least another two peaks selected from the following list: 4.7, 14.0, 15.1, 15.5, 18.3, and 18.7±0.2 degrees two theta; a powder XRD pattern with peaks at about 13.5, 15.5, 19.2, 23.7, and 24.4±0.2 degrees two theta; and a powder XRD pattern with peaks at about 4.65, 13.46, 17.63, 18.30, and 23.66±0.10 degrees two theta, processes for preparing said Sitagliptin crystalline form, and pharmaceutical compositions thereof, are provided. | 02-18-2010 |
| 20100056785 | Preparation Of Zopiclone And Its Enantiomerically Enriched Isomer - Present invention relates to an improved process for the preparation of Zopiclone and its enantiomerically enriched isomer (Eszopiclone). 6-(5-Chloropyridin-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]pyrazine is reacted with 1-chloro-carbonyl-4-methylpiperazine in the presence of alkali earth metal carbonates, hydroxides or oxides in a solvent medium to give Zopiclone. It is reacted with optically active acid in a mixture of water and water miscible organic solvent followed by work up to give Eszopiclone. The present invention also relates to process for the conversion of (R) or (S) Zopiclone to 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydro-pyrrolo-[3,4-b]-pyrazine of the intermediate which can be converted to racemic Zopiclone. | 03-04-2010 |
| 20100069637 | CRYSTALLINE SALT FORMS OF A 5,6,7,8-TETRAHYDRO-1,2,4-TRIAZOLO[4,3-a]PYRAZINE DERIVATIVE - This invention provides novel crystalline acid salt forms of 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine, i.e. sitagliptin, to processes for their preparation and isolation, and to pharmaceutical compositions comprising the same. | 03-18-2010 |
| 20100274017 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICLLY ACCEPTABLE SALTS THEREOF - There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same. | 10-28-2010 |
| 20100274018 | PROCESS FOR THE RESOLUTION OF ZOPICLONE AND INTERMEDIATE COMPOUNDS - The present invention refers to a process for the resolution into one of its enantiomers of the racemate of compound of formula (I): | 10-28-2010 |
| 20100280245 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES - A process for producing an enantiomerically enriched, pure or enriched and essentially pure compound of Formula I: | 11-04-2010 |
| 20100317856 | PROCESS FOR THE PREPARATION OF R-SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - The present invention provides processes for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof. | 12-16-2010 |
| 20100331541 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN - A process for the preparation of 2(R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]-7(8H)-pyrazinyl]-1-(2,4,5-trifluorophenyl)-2-butanamine and intermediates useful for the synthesis thereof. | 12-30-2010 |
| 20110213149 | PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE & NEW IMPURITIES IN PREPARATION THEREOF - The present invention relates to synthesis of β-amino acid derivatives of formula (I) and its salts of formula (Ia) by a novel process. The process comprises the reduction of a protected or unprotected prochiral β-amino acrylic acid or derivative there of, by using borane containing reducing agents at atmospheric pressure. The resulting racemic β-amino compound is resolved to a pure stereoisomer of formula (I), specifically to (2R)-4-oxo-4-[3-Ctrifluoromethyl)-5,6-dihydrol[1,2,4]triazolo[4,3-alpyrazin-7(8H)-yl]-1-(2,4,4-trifluorophenyl)butan-2-amine. In an embodiment the invention disclosed polymorphic forms of formula (I), phosphate salt of formula (I) and also a Dibenzoyl-L-tartaric acid salt of formula (I). | 09-01-2011 |
| 20110245498 | SOLID STATE FORMS OF SITAGLIPTIN SALTS - Crystalline forms of Sitagliptin salts, processes for preparing crystalline forms of Sitagliptin salts, and pharmaceutical compositions of Sitagliptin salts are provided. | 10-06-2011 |
| 20110245499 | Process for Resolving Zopiclone - The present invention provides a process for the preparation of the dextrorotatory isomer of zopiclone (eszopiclone). The present invention also provides eszopiclone di-p-anisolyl-L-tartrate and eszopiclone diacetyl-L-tartrate, which are useful as intermediates in a process for preparing eszopiclone. | 10-06-2011 |
| 20120010409 | IMPROVED CHEMICAL SYNTHESIS OF DIAZAINDOLES BY CHICHIBABIN CYCLIZATION - An improved synthesis method for making diazaindoles using a Chichibabin cyclization is disclosed. In particular, this method is useful for making the compound of Formula I. | 01-12-2012 |
| 20120041202 | Preparation of C-Pyrazine-Methylamines - A process for preparing a compound of formula (I) or a salt thereof: (I) wherein R1 is H or optionally substituted aryl or heteroaryl; comprising reacting 2,3-dichloropyrazine with a suitable diaryl imine followed by hydrolysis. | 02-16-2012 |
| 20120071658 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY - Provided herein are Heteroaryl Compounds having the following structure: | 03-22-2012 |
| 20120077979 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 03-29-2012 |
| 20120214997 | METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN - Disclosed are a novel, simple and low-cost method for preparing sitagliptin, as DPP-IV (dipeptidyl peptidase IV) inhibitor, which is useful in treating type 2 diabetes mellitus and key intermediates used in said preparation of sitagliptin. | 08-23-2012 |
| 20130035486 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical composition comprising the same. | 02-07-2013 |
| 20130041150 | PROCESS FOR THE PREPARATION OF CHIRAL BETA AMINO CARBOXAMIDE DERIVATIVES - The present invention provides a process for preparing a compound of formula (I), or a pharmaceutically acceptable salt thereof, having the R-configuration, of formula (IA), or S-configuration of formula (IB), selectively over the other enantiomer. | 02-14-2013 |
| 20130123501 | PROCESS FOR THE PREPARATION OF THE COMPOUND OSI-906 - Process for preparing the tyrosine kinase inhibitor OSI-906 comprises coupling Compound (2) with Compound (6) under specified conditions. | 05-16-2013 |
| 20130158264 | Polymorphs of OSI-906 - Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, pharmaceutical compositions, and uses thereof. The invention includes methods of treating diseases such as cancer, including cancer mediated at least in part by IGF-1 R and/or IR, with the polymorphs and compositions. This Abstract is not limiting of the invention. | 06-20-2013 |
| 20130158265 | SITAGLIPTIN, SALTS AND POLYMORPHS THEREOF - The present invention relates to an improved process for preparation of Sitagliptin or pharmaceutically acceptable salts thereof. The present invention further relates to novel polymorphs of Sitagliptin salts and process for preparation thereof. | 06-20-2013 |
| 20130190496 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 07-25-2013 |
| 20130245264 | PYRAZINO[2,3-D]ISOXAZOLE DERIVATIVE - The object of the present invention is to provide a compound which is useful as a production intermediate of pyrazine carboxamide derivative such as 6-fluoro-3-hydroxy-2-pyrazine carboxamide. The present invention provides a pyrazino[2,3-d]isoxazole derivative represented by the formula (I): | 09-19-2013 |
| 20130261306 | PREPARATION OF C-PYRAZINE-METHYLAMINES - A process for preparing a compound of formula (I) or a salt thereof: (I) wherein R1 is H or optionally substituted aryl or heteroaryl; comprising reacting 2,3-dichloropyrazine with a suitable diaryl imine followed by hydrolysis. | 10-03-2013 |
| 20130281695 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF - Disclosed are intermediates of Sitagliptin, a preparation process thereof, and a process for synthesizing Sitagliptin using these intermediates. Sitagliptin is synthesized by using chiral amino compounds as a raw material, without having to build a chiral center with a chiral asymmetric catalytic hydrogenation, and high-pressure hydrogenation is avoided. | 10-24-2013 |
| 20130289276 | PROCESS FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC CONVERSION - The invention provides a process for preparing 3-hydroxy-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one (Formula I), into its racemic (R/S) form or any of its optically active (S) or (R) forms or enantiomeric excess mixture of any of the forms comprising:
| 10-31-2013 |
| 20130296565 | L-MALATE SALTS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-- DIHYDRO-5H-PYRROLO[3,4-B]PYRAZINE - A novel L-malate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided. | 11-07-2013 |
| 20140005394 | PREPARATION METHOD OF INTERMEDIATE OF SITAGLIPTIN | 01-02-2014 |
| 20140051856 | NOVEL SALTS OF DPP-IV INHIBITOR - The present invention discloses new salts of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine i.e. gentisate, adipate and trifluoro acetic acid salts. The invention also describes the new. crystalline and amorphous forms of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine gentisate. The present invention also discloses novel crystalline salt form of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine hydrochloride and novel crystalline and amorphous salt forms of besylate and process for their preparation and isolation. | 02-20-2014 |
| 20140073791 | NOVEL SALTS OF SITAGLIPTIN, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention relates to pharmaceutically acceptable acid addition salts of sitagliptin, in particular anti-oxidant acid addition salts of sitagliptin and a process for its preparation. The present invention also provides a pharmaceutical composition using the pharmaceutically acceptable acid addition salts of sitagliptin. | 03-13-2014 |
| 20140081026 | PROCESS FOR THE PRODUCTION OF SITAGLIPTIN - A novel process is described for the synthesis of Sitagliptin, IUPAC name 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine, of formula (I). | 03-20-2014 |
| 20140128607 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same. | 05-08-2014 |
| 20140296521 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF - There has been a need for coelenterazine analogs that exhibit luminescence properties different from those of known coelenterazine analogs. The present invention provides the compound represented by general formula ( | 10-02-2014 |
| 20150087834 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE - The present invention relates to a method for the preparation of sitagliptin phosphate and sitagliptin phosphate anhydrous of Formula (I′) and monohydrate of Formula (I), | 03-26-2015 |
| 20150353564 | Processes for the Preparation of Chiral Beta Amino Acid Derivatives Using Asymmetric Hydrogenation Catalysts - This invention provides processes for the preparation of Sitagliptin and pharmaceutically acceptable salts thereof, said processes including enantioselective hydrogenation of a prochiral enamine using chiral ruthenium catalyst. | 12-10-2015 |
| 20160122274 | Salts of Sitagliptin, Process from the Preparation and Pharmaceutical Composition Therefore - The present invention relates to pharmaceutically acceptable acid addition salts of sitagliptin, in particular anti-oxidant acid addition salts of sitagliptin and a process for its preparation. The present invention also provides a pharmaceutical composition using the pharmaceutically acceptable acid addition salts of sitagliptin. | 05-05-2016 |
| 20160251360 | A STABLE POLYMORPH OF THE SALT OF (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZI- N-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE WITH L-TARTARIC ACID | 09-01-2016 |
| 544351000 | Triethylene diamines | 5 |
| 20130023661 | FLUORINATING REAGENTS WITH (PERFLUORALKYL) FLUOROPHOSPHATE ANION - The present invention relates to the use of compounds of the formula (I) as fluorinating reagents, to a process for the fluorination of organic compounds by reaction thereof with compounds of the formula (I), and to compounds of the formula (I). | 01-24-2013 |
| 20140350253 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST - The discovery of distinct modes of asymmetric catalysis has the potential to rapidly advance chemists' ability to build enantioenriched molecules. As an example, the use of chiral cation salts as phase-transfer catalysts for anionic reagents has enabled a vast set of enantioselective transformations. A largely overlooked analogous mechanism wherein a chiral anionic catalyst brings a cationic species into solution is itself a powerful method. The concept is broadly applicable to a number of different reaction pathways, including to the enantioselective fluorocyclization of olefins, and dearomatization of aromatic systems with a cationic electrophile-transferring (e.g., fluorinating) agent and a chiral phosphate catalyst. The reactions proceed in high yield and stereoselectivity. The compounds and methods of the invention are of particular value, especially considering the scarcity of alternative approaches. | 11-27-2014 |
| 544352000 | Process of forming, purifying, or recovering triethylene diamine per se, or salt thereof | 3 |
| 20080221326 | Shaped Body Containing a Microporous Material and at Least One Silicon-Containing Binder, Method For the Production Thereof and Its Use as a Catalyst, Particularly in a Method For Producing Triethylenediamine (Teda) - Process for producing a shaped body comprising a microporous material and at least one silicon-containing binder, which comprises the steps
| 09-11-2008 |
| 20080312439 | Work-Up in the Preparation of High-Purity Triethylenediamine - The present invention relates to a process for working up triethylenediamine (TEDA) in which TEDA is vaporized and the gaseous TEDA is introduced into a solvent, subsequently crystallized and separated off from this and the mother liquor formed is extracted with an extractant, wherein the raffinate phase obtained after the extraction stage is worked up further by adsorption in which extractant and/or by-products and intermediates present in the raffinate phase are removed therefrom. | 12-18-2008 |
| 20110144335 | PENTASIL-STRUCTURE ZEOLITHIC MATERIAL THE PRODUCTION AND USE THEREOF - Zeolite material of the pentasil type has an alkali metal and alkaline earth metal content of not more than 100 ppm and a molar ratio of Si to Al of from 250 to 1500, at least 90% of the primary particles of the zeolite material being spherical and 95% by weight of the spherical primary particles having a diameter of less than or equal to 1 μm. | 06-16-2011 |
| 544353000 | Quinoxalines (including hydrogenated) | 19 |
| 20080227981 | CHARGE TRANSPORT COMPOSITIONS AND ELECTRONIC DEVICES MADE WITH SUCH COMPOSITIONS - The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions. | 09-18-2008 |
| 20100048901 | NOVEL CURCUMIN DERIVATIVE - The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on Aβ aggregation, a degradative effect on Aβ aggregates, an inhibitory effect on β-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: | 02-25-2010 |
| 20100063285 | ANTIFUNGAL TRIAZOLE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - The present invention relates to triazole derivaties, a method for the preparation thereof, and a pharmaceutical composition containing the same as an active ingredient. The inventive triazole derivaties have an excellent antifungal activity against various pathogens. | 03-11-2010 |
| 20100105906 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES - This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula | 04-29-2010 |
| 20100121062 | Slow Release of Organoboronic Acids in Cross-Coupling Reactions - A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture: | 05-13-2010 |
| 20100222587 | COMPOSITIONS AND METHODS FOR THE INTRAOCULAR TRANSPORT OF THERAPEUTIC AGENTS - Membrane transporter-targeted therapeutic agents and methods of making and using the same. | 09-02-2010 |
| 20120302751 | Carbazole Derivative with Heteroaromatic Ring, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Carbazole Derivative with Heteroaromatic Ring - Disclosed is a carbazole derivative and a light-emitting element, a light-emitting device, and an electronic device using thereof. The carbazole derivative possesses an oxadiazole moiety or a quinoxaline moiety as a heteroaromatic ring having an electron-transporting property and a carbazole moiety having a hole-transporting property. The ability of the carbazole derivative to transport both electrons and holes and its large excitation energy larger than a triplet excitation energy of a phosphorescent compound allow the formation of a phosphorescent light-emitting element having well-controlled carrier balance, which contributes to the formation of light-emitting devices and electronic devices that are capable of being driven at a low voltage, have a long lifetime, and consume low power. The detailed structure of the carbazole derivative is defined in the specification. | 11-29-2012 |
| 20130012708 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS - A compound represented by the formula (1): | 01-10-2013 |
| 20130165655 | BENZODITHIOPHENE ORGANIC SEMICONDUCTIVE MATERIAL AND ITS PREPARATION METHOD AND USE - The present invention relates to optoelectronic materials field, and it discloses a benzodithiophene organic semiconductive material with the following structural formula (P): | 06-27-2013 |
| 20140088306 | RADIOACTIVE FLUORINE-LABELED QUINOXALINE COMPOUND - Provided is a compound effective as a diagnostic imaging probe targeting amyloid and an agent for Alzheimer's disease diagnosis including the compound. | 03-27-2014 |
| 20140179921 | CHEMICAL COMPOUNDS - A compound of formula I | 06-26-2014 |
| 20150094468 | NOVEL DIAMINE COMPOUND AND METAL COMPLEXES, AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS - The present invention relates to a novel diamine compound represented by the general formula (1), a ruthenium-diamine complex, an iridium-diamine complex, and a rhodium-diamine complex having the diamine compound as a ligand. Furthermore, the present invention relates to methods for selectively producing optically active compounds by using any of these complexes as a catalyst. | 04-02-2015 |
| 544354000 | Chalcogen bonded directly to diazine ring carbon | 4 |
| 20090048445 | Method of Synthesizing Quinoxaline Derivative by Microwave Irradiation - There is disclosed a method of synthesizing a quinoxaline derivative in which toxicity, corrosiveness and permeation are low and which is excellent in safety and which attains a reduced reaction time, a greatly improved yield and excellent economical efficiency. The object is achieved by a method of synthesizing a quinoxaline derivative which comprises adsorbing a benzofuroxan derivative and a β-diketone derivative on a solid support, and then heating the derivatives in a solid state by microwave irradiation to dehydrocyclize them. | 02-19-2009 |
| 20120245352 | Quinoxaline Compounds and Derivatives - The present invention provides oxazine compounds, method of using and method of making oxazine compounds and its pharmaceutical use. | 09-27-2012 |
| 20140073792 | NITROGENATED HETEROCYCLIC COMPOUND AND AGRICULTURAL OR HORTICULTURAL FUNGICIDE - An agricultural or horticultural fungicide contains as an active ingredient thereof at least one compound selected from the group consisting of nitrogenated heterocyclic compounds represented by formula (I) (wherein, R represents a group represented by CR | 03-13-2014 |
| 20160200690 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | 07-14-2016 |
| 544355000 | Having -C(=X)-, wherein X is chalcogen, bonded directly to diazine ring carbon | 2 |
| 20130109856 | NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS | 05-02-2013 |
| 20140039189 | NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS - The present invention relates to a novel process for the preparation of compounds of general formula (I) | 02-06-2014 |
| 544356000 | Halogen or nitrogen attached directly to diazine ring carbon by nonionic bonding | 1 |
| 20130317223 | Slow Release of Organoboronic Acids in Cross-Coupling Reactions - A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture: | 11-28-2013 |
